Daily FNArena News

Australia’s retail sales numbers for May were far stronger than the market had expected, leading economist to question whether or not the RBA will feel the need to move again on rates.

Life science stocks are not exactly investor favourites at present but ABN Amro Morgans sees Acrux as a standout in the sector given its technology and solid financial position.

The Fed is banking on US inflation eventually falling due to economic weakness, but Morgan Stanley warns it may take longer than hoped. There are also implications for Australia.

The RBA has clearly become more concerned about inflation, but still anticipates a fall ahead.

As expected, the RBA has left its cash rate unchanged at 7.25%.

All of a sudden, the mobile phone is emerging as the most important medium for the future of advertising.

Babcock & Brown received some good news yesterday when its banking syndicate waived the need to review the facility but with asset sales still needed brokers are not getting too excited.

CLSA’s June survey into Chinese manufacturing confirms Chinese manufacturers continue battling with higher input costs.

Austock Securities has toured the assets of Macquarie Infrastructure Fund and this has not changed the stockbroker’s positive view on the stock at current levels.

March quarter GDP data was weak and the restrictive level of interest rates at present makes a recession likely in New Zealand.